A phase II, Open-Label, Single-Arm Trial of Carboplatin Plus Etoposide with Bevacizumab and Atezolizumab in Patients with Extended-Stage Small-Cell Lung Cancer (CeLEBrATE study): Background, Design and RationaleElisa Andrini, Andrea Ardizzoni, Andrea Bonetti et al.|Future Oncology|2022Cited by 7
Carboplatin, etoposide, atezolizumab, and bevacizumab in the first-line treatment of patients with extensive stage small-cell lung cancer: the GOIRC-01-2019 CeLEBrATE studyGiuseppe Lamberti, Andrea Ardizzoni, Karim Rihawi et al.|Journal for ImmunoTherapy of Cancer|2025Cited by 5